Satellos Bioscience Inc MSCL.TO is expected to report results on March 9 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for Satellos Bioscience Inc is for a loss of 8 cents per share.
The one available analyst rating on the shares is "strong buy".
The average consensus recommendation for the biotechnology & medical research peer group is also "Strong Buy".
Wall Street's median 12-month price target for Satellos Bioscience Inc is $40.00, about 224.4% above its last closing price of $12.33
This summary was machine generated March 6 at 12:38 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)